Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (1 active)
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (5)
Type
Type
Guidance (302)
Guidance programme
(
1 selected
)
Guidance programme
Clinical guidelines (27)
Diagnostics guidance (9)
Health technology evaluations (11)
Highly specialised technologies guidance (8)
Interventional procedures guidance (10)
Medical technologies guidance (11)
NICE guidelines (30)
Public health guidelines (1)
Technology appraisal guidance (302)
Apply filters
Showing 291 to 300 of 302
Sort by
Title
Date
Apply sorting
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565
Technology appraisal guidance
TBC
Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040]
Technology appraisal guidance
TBC
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable [ID6291]
Technology appraisal guidance
TBC
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]
Technology appraisal guidance
TBC
Vibegron for treating symptoms of overactive bladder ID6300
Technology appraisal guidance
TBC
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]
Technology appraisal guidance
TBC
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]
Technology appraisal guidance
22 November 2017
Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]
Technology appraisal guidance
TBC
Zanubrutinib for treating relapsed or refractory marginal zone lymphoma [ID5085]
Technology appraisal guidance
17 July 2024
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]
Technology appraisal guidance
TBC
Previous page
1
…
28
29
Current page
30
31
Page
30
of
31
Next page
Results per page
10
25
50
All
Back to top